Suggest Edits

Be The First To
Add Photos

Headquarters Oxford, United Kingdom
Size 50 to 149 Employees
Founded Unknown
Type Company - Public (OXB)
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company uses gene therapy and immunotherapy to develop treatments for cancer, as well as neurodegenerative and ocular diseases. Its four ocular gene therapies are partnered with Sanofi; the company works with Pfizer on another targeted antibody therapy. The company has three lead products: TroVax, ProSavin, and RetinoStat (being developed with Sanofi). TroVax is in late-stage clinical trials for the treatment of prostate cancer. ProSavin is being tested to treat Parkinson's disease... More

Working at Oxford BioMedica

Posted by employees

Employees say it's “OK”   2 ratings

3.0

Not yet rated.

 

Oxford BioMedica CEO and Director John Dawson

John Dawson

CEO and Director

Exiting prospects.

  Former Employee

Pros: Great people and facilities. Exciting product pipeline from many angles. Takes time out to celebrate and reward staff. Opportunity to work on genuinely important and interesting topics of your into bioscience and biomanufacturing. Full Review

More Oxford BioMedica Ratings & Reviews ( 2)

Oxford BioMedica Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Worked for Oxford BioMedica? Contribute to the Community!